



PRESS RELEASE

PledPharma AB
Stockholm October 21, 2019

Nomination Committee appointed for the 2020 Annual General Meeting in PledPharma

Stockholm, October 21, 2019. The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 23, 2020. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to participate in the committee.

The following members have been appointed by the following shareholders:

Nortal Investments AB: Staffan Persson
Cidro Förvaltning AB: Peter Lindell
Fjärde AP-fonden: Jannis Kitsakis

In total, the Nomination Committee represents ca 39% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Peter Lindell and Jannis Kitsakis are also independent in relation to Nortal Investments AB, which is the largest shareholder in the company in terms of votes.

The Nomination Committee is expected to elect Staffan Persson as chairman. Håkan Åström (Chairman of PledPharma) and Astrid Samuelsson (Handelsbanken Asset Management) have been nominated to co-opt to the Nomination Committee.

The Committee's assignment is to present to the Annual General Meeting proposals regarding Chairman and other members of the board as well as remuneration to the Board's members. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2021.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com

For further information, please contact:

Yilmaz Mahshid, CFO
Tel. +46 (0)72 231 68 00
Yilmaz.mahshid@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project **PledOx**[®] is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate **Aladote**[®] is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote[®] has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on Nasdaq First North Growth Market. Erik Penser Bank is the company's Certified Adviser (tel +46 8 463 83 00, certifiedadviser@penser.se). For more information, see <http://www.pledpharma.com/>